The immunological effects of concomitant highly active antiretroviral therapy and liposomal anthracycline treatment of HIV-1-associated Kaposi's sarcoma

Ben Esdaile, Matt Davis, Simon Portsmouth, Debashis Sarker, Mark Nelson, Brian Gazzard, Mark Bower

Research output: Contribution to journalArticlepeer-review

22 Citations (Scopus)

Abstract

A combination of highly active antiretroviral therapy (HAART) and liposomal anthracycline chemotherapy is the standard of care for advanced HIV-associated Kaposi's sarcoma, despite concerns that the chemotherapy may adversely affect lymphocyte subsets and HIV viraemia. We showed in 50 patients that liposomal anthracyclines used with HAART did not lead to a significant loss of CD4 or CD8 cells or an increase in HIV-1 viral load during or up to 12 months after chemotherapy.
Original languageEnglish
Pages (from-to)2344-7
Number of pages4
JournalAids
Volume16
Issue number17
Publication statusPublished - 22 Nov 2002

Keywords

  • Adult
  • Antibiotics, Antineoplastic
  • Antiretroviral Therapy, Highly Active
  • Drug Therapy, Combination
  • Follow-Up Studies
  • HIV Infections
  • HIV-1
  • Humans
  • Immunity, Cellular
  • Liposomes
  • Male
  • Middle Aged
  • Sarcoma, Kaposi
  • T-Lymphocyte Subsets
  • Viral Load

Fingerprint

Dive into the research topics of 'The immunological effects of concomitant highly active antiretroviral therapy and liposomal anthracycline treatment of HIV-1-associated Kaposi's sarcoma'. Together they form a unique fingerprint.

Cite this